LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Listă Acțiuni・Cytokinetics Inc

Cytokinetics Inc

Deschisă

Sector Sănătate

56.59 1.36

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

55.21

Maxim

56.62

Indicatori cheie
By Trading Economics
Venit	-7.7M -143M
Vânzări	24M 25M
EPS	0.08
Marjă de profit	-570.761
Angajați	423
EBITDA	-622K -117M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+46.47 upside

Dividende
By Dow Jones
Următoarele câștiguri	31 oct. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	-58M 5.9B
Deschiderea anterioară	55.23
Închiderea anterioară	56.59

Sentimentul știrilor

By Acuity

50%

97 / 365 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

54.22 / 56.275 Suport & Rezistență

Cytokinetics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 iun. 2024, 15:26 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

11 ian. 2024, 17:47 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Cytokinetics Shares Slide as Novartis Reportedly Shies Away From Deal

8 ian. 2024, 18:28 UTC

Principalele dinamici ale pieței

Achiziții, Fuziuni, Preluări

Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 iun. 2024, 14:14 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

11 ian. 2024, 17:47 UTC

Top știri

Achiziții, Fuziuni, Preluări

Novartis Pursuit of Cytokinetics Cools -- Update

11 ian. 2024, 17:19 UTC

Top știri

Achiziții, Fuziuni, Preluări

Novartis Pursuit of Cytokinetics Cools -- WSJ

11 ian. 2024, 17:19 UTC

Achiziții, Fuziuni, Preluări

Swiss Drug Maker Had Been Expected to Clinch Deal for Heart-Drug Developer as Soon as This Week -- WSJ

11 ian. 2024, 17:19 UTC

Achiziții, Fuziuni, Preluări

Novartis Pursuit of Cytokinetics Cools, Sources Say -- WSJ

8 ian. 2024, 21:42 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout. -- IBD

8 ian. 2024, 19:13 UTC

Achiziții, Fuziuni, Preluări

Cytokinetics Rockets 14% As Novartis Reportedly Nears A Buyout Deal -- IBD

8 ian. 2024, 18:25 UTC

Achiziții, Fuziuni, Preluări

Novartis, Cytokinetics Near Merger: Report -- MarketWatch

8 ian. 2024, 18:14 UTC

Top știri

Achiziții, Fuziuni, Preluări

Novartis in Advanced Talks to Buy Cytokinetics -- Update

8 ian. 2024, 17:56 UTC

Top știri

Achiziții, Fuziuni, Preluări

Novartis in Advanced Talks to Buy Cytokinetics -- WSJ

8 ian. 2024, 17:56 UTC

Achiziții, Fuziuni, Preluări

Deal Could Be Reached as Soon as This Week, Sources Say -- WSJ

8 ian. 2024, 17:56 UTC

Achiziții, Fuziuni, Preluări

Novartis in Advanced Talks to Buy Cytokinetics, Sources Say -- WSJ

31 oct. 2023, 17:49 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Cytokinetics May Have Some Tire Kickers -- Market Talk

Comparație

Modificare preț

Cytokinetics Inc Așteptări

Obiectiv de preț

By TipRanks

46.47% sus

Prognoză pe 12 luni

Medie 81.85 USD 46.47%

Maxim 107 USD

Minim 60 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCytokinetics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 14 analiști care au acordat evaluări ale acțiunilor Cytokinetics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

54.22 / 56.275Suport & Rezistență

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

97 / 365 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Cytokinetics Inc

Cytokinetics, Incorporated is a late-stage biopharmaceutical company that is focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. The Company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company is conducting METEORIC-HF, a second Phase III clinical trial of omecamtiv mecarbil. It is also developing aficamten, a cardiac myosin inhibitor, for the potential treatment of HCM. The Company also conducts research and development on novel treatments for disorders involving muscle function beyond muscle contractility. The Company’s lead drug candidates in clinical development are omecamtiv mecarbil, a cardiac myosin activator; CK-136, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.